Recent Posts
- Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update November 13, 2023
- Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production November 3, 2023
- Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program October 30, 2023
Pipeline and Technology
Corporate Address
Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY 10017
admin@eyenovia.com
EYENOVIA ANNOUNCES APPOINTMENTS OF DR. ELLEN STRAHLMAN AND DR. RAM PALANKI AS NEW AND INDEPENDENT MEMBERS OF ITS BOARD OF DIRECTORS
NewsEyenovia CEO, CMO and Chairman Dr. Sean Ianchulev to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022
NewsEyenovia Announces Poster Presentation at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting
NewsEyenovia Announces Positive Study Results Demonstrating that its Optejet® Delivery Technology Reduces Conjunctival Cell Toxicity from Preserved Ophthalmic Solutions to a Level Comparable with Non-Preserved Solutions
NewsEyenovia Concludes Type A Meeting with FDA Related to MydCombi™ NDA Resubmission
NewsEyenovia Announces Changes to the Board of Directors
NewsEyenovia Reports Third Quarter 2021 Financial Results
NewsEyenovia to Participate in Myopia Panel Discussion at the Eyecelerator @AAO 2021 Meeting
NewsEyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopia
NewsEyenovia Announces Reclassification of MydCombi™ as Drug-Device Combination Product by FDA
News